Orthofix Medical's reported net sales for Q4 FY23 not only surpassed the consensus estimates but also showed significant year-over-year growth. This outperformance is likely to be viewed positively by investors and could lead to a short-term uptick in the stock price, as it suggests the company is growing and potentially gaining market share. The reported figures reflect both a strong reported basis growth and a solid pro forma basis growth, which may reassure investors about the company's underlying performance.